Investigating CREB1 signaling as a novel therapeutic target in multiple myeloma

Description

Multiple myeloma (MM) is a rare neoplastic disorder characterized by uncontrolled clonal proliferation of malignant plasma cells in the bone marrow (BM). In the last decade, the therapeutic approaches to treat MM patients have been improved. Nevertheless, the urgent need to identify new therapeutic targets remains to develop more effective strategies against this uncurable disease. The principal aim of my research project was investigate the biology and the interactome of the trascription factor CREB1 (Cyclic AMP-responsive element-binding protein 1) in high-risk multiple myeloma models to provide insights for novel therapeutic opportunities in MM. The definition of genes regulated by CREB1 signaling can help to identify tailored therapeutic strategies for patients with t(4;14) or high CD56 expression. Moreover, the inhibition of CREB1 signaling can promote cell death and improve anti-MM activity. My research year in Dr. Cottini Lab was sustained by IMS award that gave me the opportunity to improve my knowledges in the field of multiple myeloma in an international work environment.